泊马度胺（CAS 19171-19-8）：分子式 C13H11N3O4、分子量 273.24；类别 医药中间体。
| CAS号 | 19171-19-8 |
|---|---|
| 分子式 | C13H11N3O4 |
| 分子量 | 273.24 |
| LogP | 0.2 |
| 应用领域 | Uses: MEDICATION、Angiogenesis Inhibitors、Immunologic Factors、Methods of Manufacturing: Pomalidomide is synthesized in two main steps using commercially available well defined starting materials with acceptable specifications. The first step consists of a coupling reaction in which the starting materials react to form crude pomalidomide. The second step is a purification process consisting on filtration、crystallization and drying to obtain the final drug substance.、Preparation: G. W. Muller et al.、World Intellectual Property Organization patent 9803502、eidem、United States of America patent 6335349 (1998、2002 both to Celgene).、Formulations、Preparations: Table: Pomalidomide Preparations [Table#8206] |
| 类别 | 医药中间体 |
登记用途：Uses: MEDICATION、Angiogenesis Inhibitors、Immunologic Factors、Methods of Manufacturing: Pomalidomide is synthesized in two main steps using commercially available well defined starting materials with acceptable specifications. The first step consists of a coupling reaction in which the starting materials react to form crude pomalidomide. The second step is a purification process consisting on filtration、crystallization and drying to obtain the final drug substance.、Preparation: G. W. Muller et al.、World Intellectual Property Organization patent 9803502、eidem、United States of America patent 6335349 (1998、2002 both to Celgene).、Formulations、Preparations: Table: Pomalidomide Preparations [Table#8206]。
泊马度胺 是一种化工化合物，登记 CAS 号为 19171-19-8，分子式 C13H11N3O4（分子量 273.24），归属于医药中间体大类化工原料。
登记 CAS 号：19171-19-8
其分子式 C13H11N3O4 由 13 个碳、11 个氢、3 个氮、4 个氧 组成。
别名/同义词：泊马度胺 · Pomalidomide
所属分类：医药中间体
泊马度胺 的 CAS 登记号为 19171-19-8。
分子式 C13H11N3O4，分子量 273.24。
别名/同义词：泊马度胺、Pomalidomide。
登记用途：Uses: MEDICATION、Angiogenesis Inhibitors、Immunologic Factors、Methods of Manufacturing: Pomalidomide is synthesized in two main steps using commercially available well defined starting materials with acceptable specifications. The first step consists of a coupling reaction in which the starting materials react to form crude pomalidomide. The second step is a purification process consisting on filtration、crystallization and drying to obtain the final drug substance.、Preparation: G. W. Muller et al.、World Intellectual Property Organization patent 9803502、eidem、United States of America patent 6335349 (1998、2002 both to Celgene).、Formulations、Preparations: Table: Pomalidomide Preparations [Table#8206]。
所属分类：医药中间体。
泊马度胺（CAS 19171-19-8）的独立参考数据，整理自公开化学数据库。
| CAS Registry Number | 19171-19-8 |
|---|---|
| PubChem CID | 134780 |
| Molecular formula | C13H11N3O4 |
| IUPAC name | 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| UNII (FDA) | D2UX06XLB5 |
| Molecular Weight | 273.24 |
|---|---|
| XLogP3 | 0.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 1 |
| Exact Mass | 273.07495584 |
| Monoisotopic Mass | 273.07495584 |
| Topological Polar Surface Area | 110 |
| Heavy Atom Count | 20 |
Pomalidomide; 19171-19-8; Actimid; Pomalyst; CC-4047; Imnovid; 4-Aminothalidomide; 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; IMID-3; 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide; IMiD 3; CC 4047; Pomalidomida; D2UX06XLB5
| Reported hazard statements | H361 (10.8%), H373 (81.1%) |
|---|
H360FD (75.7%): May damage fertility; May damage the unborn child [Danger Reproductive toxicity]
H361 (10.8%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
Pomalidomide · CAS 19171-19-8 · C13H11N3O4. UNII D2UX06XLB5.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: Pomalidomide